Linking higher amyloid beta 1-38 (Aβ(1-38)) levels to reduced Alzheimer's disease progression risk
- Luisa Sophie Schneider
- , Silka Dawn Freiesleben
- , Gerard van Breukelen
- , Xiao Wang
- , Frederic Brosseron
- , Michael T. Heneka
- , Stefan Teipel
- , Luca Kleineidam
- , Melina Stark
- , Nina Roy-Kluth
- , Michael Wagner
- , Annika Spottke
- , Matthias Schmid
- , Sandra Roeske
- , Christoph Laske
- , Matthias H. Munk
- , Robert Perneczky
- , Boris Stephan Rauchmann
- , Katharina Buerger
- , Daniel Janowitz
- Charité – Universitätsmedizin Berlin
- Experimental and Clinical Research Center (ECRC)
- German Center for Neurodegenerative Diseases (DZNE)
- University of Maastricht
- University of Luxembourg
- Rostock University Medical Center
- University of Bonn and University Hospital Bonn
- University of Bonn
- University Clinic Tuebingen
- Universitätsklinikum Tübingen
- Ludwig-Maximilians-Universität München
- Imperial College London
- Munich Cluster for Systems Neurology (SyNergy)
- University of Sheffield
- Otto-von-Guericke University
- University of Cologne
- University of Cologne
- University of Aveiro
- University Medical Center
- The University of Edinburgh Medical School
Research output: Contribution to journal › Article › peer-review